FindTrial
Sign In

NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519113-59-00
Enrollment
202
Registered
2024-11-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Brief summary

Recurrence-free survival: Recurrence is defined as recurrence or death, whichever comes first. Recurrence is defined as emergence of ≥ 1cm nodules enhanced at arterial phase followed by washout at portal or late phase observed on MRI, or any atypical nodule on imaging with histological features of HCC (EASL guidelines). Emergence of extrahepatic metastasis is also considered as a recurrence. Patients will be followed by MRI, 3, 6, 9, 12, 15, 18, 21and 24 months after randomization

Interventions

DRUGBEVACIZUMAB
DRUGATEZOLIZUMAB

Sponsors

Centre Hospitalier Universitaire De Montpellier
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival: Recurrence is defined as recurrence or death, whichever comes first. Recurrence is defined as emergence of ≥ 1cm nodules enhanced at arterial phase followed by washout at portal or late phase observed on MRI, or any atypical nodule on imaging with histological features of HCC (EASL guidelines). Emergence of extrahepatic metastasis is also considered as a recurrence. Patients will be followed by MRI, 3, 6, 9, 12, 15, 18, 21and 24 months after randomization—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026